Form 8-K · Current report
Quest Diagnostics 8-K, filed Oct 22, 2026
- Filed
- CIK
- 0001022079
- Accession no.
- 0001022079-26-000097
Summary
Quest Diagnostics reported third-quarter 2026 revenues of $3.10 billion, up 10.0% from a year earlier, with reported diluted EPS of $2.78 and adjusted diluted EPS of $3.00, and raised its full-year 2026 revenue and EPS guidance. Chairman, CEO and President Jim Davis attributed the growth to strength across the company's physician, hospital and consumer channels plus productivity gains from automation and AI.
Key points
- Third-quarter net revenues were $3.097 billion, up 10.0% year over year, with requisition volume up 14.5% and revenue per requisition down 4.2%.
- Reported diluted EPS was $2.78, up 28.7%; adjusted diluted EPS was $3.00, up 15.4%.
- Full-year 2026 guidance was raised to revenues of $12.065–12.105 billion, reported diluted EPS of $10.21–10.31, and adjusted diluted EPS of $11.25–11.35.
- Quest announced that U.S. iPhone and iPad users will be able to purchase a Quest lab test panel with over 50 biomarkers through the Apple Health app later this year, and extended its AD-Detect menu with the FDA-cleared Roche Elecsys pTau217 blood test.
Written by an AI model from the filing text. It can be incomplete or wrong; the filing on SEC.gov is the record.
Items reported
- 2.02Results of Operations and Financial Condition
- 9.01Financial Statements and Exhibits
From the filing
Item 2.02. Results of Operations and Financial Condition On October 22, 2026, Quest Diagnostics Incorporated (the "Company") issued a press release announcing, among other things, its results for the quarter ended September 30, 2026. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated by reference herein. Item 9.01. Financial Statements and Exhibits d. Exhibit 99.1 Press release of Quest Diagnostics Incorporated dated October 22, 2026, announcing, among other things, its results for the quarter ended September 30, 2026. 104 The cover page from this current report on Form 8-K, formatted in Inline XBRL. …
An excerpt of the text as filed with the SEC, cut for length.
Readster writes AI-generated summaries of public filings for research purposes only. Summaries can be incomplete or wrong — check the original filing on SEC.gov before relying on it. Nothing here is investment, legal or medical advice.